Rel - reticuloendotheliosis oncogene Gene

Also Known as c-Rel

Species: Mus musculus

Gene Type: protein coding
Gene ID: 19696

About Rel

Chromosome 11: 23,686,847-23,720,970 reverse strand.GRCm39:CM001004.3

This gene has 1 transcript (splice variant), 208 orthologues, 4 paralogues and is associated with 72 phenotypes. Broad expression in spleen adult (RPKM 6.1), thymus adult (RPKM 3.) and 21 other tissues.

Summary

Enables DNA-binding transcription factor activity. Acts upstream of or within positive regulation of interleukin-12 production and positive regulation of transcription, DNA-templated. Located in cytoplasm and nucleus. Is expressed in eye; genitourinary system; and heart. Orthologous to human REL (REL proto-oncogene, NF-kB subunit). [provided by Alliance of Genome Resources, Apr 2022]

Rel Products (1)

mRNA Protein Name
NM_009044.3 NP_033070.2 proto-oncogene c-Rel

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Références Source
enables DNA-binding transcription factor activity IDA
IDA: Inferred from direct assay
14568984 MGI
enables protein binding IPI
IPI: Inferred from physical interaction
15220916 MGI
Biological Process GO Annotation Evidence Références Source
acts upstream of or within cytokine production IMP
IMP: Inferred from mutant phenotype
15220916 MGI
acts upstream of or within positive regulation of DNA-templated transcription IDA
IDA: Inferred from direct assay
14568984 MGI
acts upstream of or within positive regulation of interleukin-12 production IMP
IMP: Inferred from mutant phenotype
14568984 MGI
Cellular Component GO Annotation Evidence Références Source
located in cytoplasm IDA
IDA: Inferred from direct assay
21874024 MGI
located in nucleus IDA
IDA: Inferred from direct assay
15220916 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Rel Protein Structure

RHD-n_c-Rel

RHD-n_c-Rel: cd07933 (7 - 178)

IPT_NFkappaB

IPT_NFkappaB: cd01177 (185 - 280)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 588 a.a.
Protein Preferred Names Protein Names

proto-oncogene c-Rel

  • C-Rel proto-oncogene protein

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Nom du produit Effect
Pureté Rare Diseases
HY-17371A (rel)-Oxaliplatin / Unkown

Clinical Phase

Bioactive Molecules (3)
Cat. No. Nom du produit Effect
Pureté Phase
HY-122359A rel-Levormeloxifene / Phase 3
HY-117283 rel-Aprikalim Control / Phase 2
HY-135238 (rel)-RSD 921 Agonist / Phase 2

Pre-clinical Phase

Bioactive Molecules (147)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-15917 DL-Dithiothreitol Inhibitor 99.8% Unkown
HY-Y1881B Copper sulfate pentahydrate, for cell culture, 98% 99.99% Unkown
HY-12276 MALT1 inhibitor MI-2 Inhibitor 99.73% Unkown
HY-Y1881A Copper sulfate pentahydrate, 99.9% 99.90% Unkown
HY-124179 IT-901 Inhibitor 99.32% Unkown
HY-B1890 (±)-Catechin Inhibitor 99.51% Unkown
HY-139426A (rel)-ML-SI3 98.94% Unkown
HY-76387 rel-(2R,3S)-1,2,3,4-Tetrahydro-1,4-methanonaphthalene-2,3-diol 99.81% Unkown
HY-119940 MC180295 Inhibitor 98.07% Unkown
HY-121508 (E/Z)-IT-603 Inhibitor 99.29% Unkown
HY-160477 DC-SX029 Inhibitor 98.07% Unkown
HY-I1030 rel-(1R,2R)-1-(6-Bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol 99.01% Unkown
HY-482931C rel-(2R,3R)-2-Phenylpiperidin-3-amine dihydrochloride 99.85% Unkown
HY-113068 (rel)-β-Tocopherol Inhibitor 99.91% Unkown
HY-120006A (rel)-AR234960 Agonist 98.95% Unkown
HY-160440 rel-VU6021625 Control 99.67% Unkown
HY-B0757A (±)-α-Tocopherol nicotinate 99.80% Unkown
HY-N0683A rel-α-Vitamin E Inhibitor 70.0% Unkown
HY-70045 (1R,2S,4R)-rel-1-Azabicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride 95.0% Unkown
HY-W045799 rel-2-(tert-Butoxycarbonyl)octahydrocyclopenta[c]pyrrole-3a-carboxylic acid 97.0% Unkown
HY-W547983 rel-Ethyl (2R,3S)-2,3-dimethylcyclopropanecarboxylate 96.69% Unkown
HY-114324A rel-PROTAC PARP1 degrader 98.32% Unkown
HY-W061724 rel-((1S,2R)-2-(Methoxycarbonyl)cyclopropane-1-carboxylic acid) / Unkown
HY-W364968 rel-(1S,2R)-2-(((tert-butoxycarbonyl)amino)methyl)cyclopropane-1-carboxylic acid 98.90% Unkown
HY-112163A rel-Zotatifin 97.32% Unkown
HY-101387 rel-ACPT-I Agonist 99.0% Unkown
HY-78745 rel-(2R,3S,4R,5S)-3-(3-Chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carboxylic acid tert-butyl ester 98.85% Unkown
HY-W073502 rel-(1r,4r)-4-Aminocyclohexane-1-carbonitrile hydrochloride ≥97.0% Unkown
HY-W710914A rel-HDMP 28 hydrochloride 99.70% Unkown
HY-128838A (rel)-PROTAC ERRα Degrader-1 98.18% Unkown
HY-B0176AS rel-Sertraline-d3 hydrochloride Inhibitor 99.56% Unkown
HY-103451A rel-(R,R)-THC Antagonist 99.1% Unkown
HY-18941B (rel)-Eglumegad Agonist 97.0% Unkown
HY-77493 (rel)-Tivantinib Inhibitor 96.45% Unkown
HY-N2207 rel-(8R,8'R)-Dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan 99.95% Unkown
HY-RS11823 REL Human Pre-designed siRNA Set A / Unkown
HY-RS11824 Rel Mouse Pre-designed siRNA Set A / Unkown
HY-128732 rel-(2R,3S)-2,3-Dihydroxysuccinic acid hydrate 99.96% Unkown
HY-166238 rel-Linoleic acid-biotin 95.0% Unkown
HY-I1031 rel-Bedaquiline 97.56% Unkown
HY-N2379 rel-(2R,3S)-3-Phenylisoserine methyl ester 99.12% Unkown
HY-111537 rel-AZ5576 Inhibitor / Unkown
HY-141726S rel-(αR,βR)-β-(2,4-Difluorophenyl)-β-hydroxy-α-methyl-1H-1,2,4-triazole-1-butanoic acid-d3 / Unkown
HY-141788S rel-4-Nitrobenzyl (2S,4R)-2-(dimethylcarbamoyl)-4-hydroxypyrrolidine-1-carboxylate-d6 / Unkown
HY-100243A Norcisapride / Unkown
HY-10121D rel-Asenapine hydrochloride / Unkown
HY-101512D rel-A-395 hydrochloride Inhibitor / Unkown
HY-10406B rel-Talmapimod hydrochloride / Unkown
HY-105281 rel-(E)-BMY 21950 sodium / Unkown
HY-106874B rel-Delequamine / Unkown
HY-106899A (rel)-MK 287 Control / Unkown
HY-109092A rel-Licogliflozin Inhibitor / Unkown
HY-110020 rel-O-2050 Antagonist / Unkown
HY-113239S1 rel-Hydroxycotinine-d3 / Unkown
HY-113756B rel-Latanoprost acid Agonist / Unkown
HY-120493 (rel)-AM-6226 Agonist / Unkown
HY-122495 rel-Quinpirole dihydrochloride Agonist / Unkown
HY-123876 AS2677131 Inhibitor / Unkown
HY-12422C rel-(2S,3R)-Voruciclib Inhibitor / Unkown
HY-12422E rel-(2S,3R)-Voruciclib hydrochloride / Unkown
HY-124874 (rel)-Asperparaline A Antagonist / Unkown
HY-12650A (rel)-Mirogabalin Inhibitor / Unkown
HY-128837A (rel)-Nutlin carboxylic acid / Unkown
HY-13047A rel-S-(+)-Mecamylamine hydrochloride Antagonist / Unkown
HY-13204S1 rel-Biperiden-d5 Inhibitor / Unkown
HY-13204S2 rel-Biperiden EP impurity A-d5 Inhibitor / Unkown
HY-13204S3 rel-Biperiden EP impurity B-d5 Inhibitor / Unkown
HY-132210 rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane Antagonist / Unkown
HY-135286B (±)-rel-Neomenthol / Unkown
HY-13607A (rel)-BMS-641988 Antagonist / Unkown
HY-13631Q (1R,9R)-rel-Exatecan / Unkown
HY-140902 rel-Biotin-PEG3-C3-NH2 / Unkown
HY-143785S rel-Saxagliptin-15N,d2 hydrochloride / Unkown
HY-144681A rel-Ceperognastat Inhibitor / Unkown
HY-14588S (rel)-Lopinavir-d8 Inhibitor / Unkown
HY-14879E rel-Avibactam sodium Inhibitor / Unkown
HY-151216S rel-Paroxetine-d4 hydrochloride / Unkown
HY-15322A (rel)-PRT062607 Inhibitor / Unkown
HY-15793A Trans (2,3)-Dihydrotetrabenazine Inhibitor / Unkown
HY-173388A rel-TLR4-IN-2 Inhibitor / Unkown
HY-17423S1 rel-Abacavir-d4 98.3% Unkown
HY-17447SA Tranylcypromine-d5 hydrochloride Inhibitor 99.42% Unkown
HY-178240 rel-(1S,2R)-Dihydro bupropion Inhibitor / Unkown
HY-181796 TLR7 antagonist-1 / Unkown
HY-18295A rel-Erteberel Agonist 99.63% Unkown
HY-185229B rel-CTR/AMYR agonist-1 Agonist / Unkown
HY-18617 rel-SB-612111 hydrochloride Inhibitor / Unkown
HY-18957A rel-Lifirafenib Control / Unkown
HY-65039A rel-Boc-Hyp-OMe / Unkown
HY-78746A (3S,4R,5S)-rel-3-(3-Chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-neopentylpyrrolidine-2-carboxylic acid 96.90% Unkown
HY-B0141S7 rel-Estradiol-13C6 / Unkown
HY-B1890S (±)-Catechin-13C3 Inhibitor / Unkown
HY-N10837 rel-3R-Methoxy-4S-furanogermacra-1E,10(15)-dien-6-one / Unkown
HY-N1384B (rel)-Ambroxide 98.0% Unkown
HY-N15739 (rel)-ent-Chromazonarol / Unkown
HY-N16764 (rel)-Salcolin A / Unkown
HY-N16800 rel-Medioresinol / Unkown
HY-N17087 (rel)-3-Hydroxy-p-menth-1-en-6-one / Unkown
HY-N17765 rel-(7R,8'R,8S)-Forsythialan C / Unkown
HY-N17783 rel-Sanleng acid / Unkown
HY-N18114 rel-(E)-6,7-Transdihydroxyligustilide / Unkown
HY-N18199 rel-Bornyl cinnamate Inhibitor / Unkown
HY-N19740 rel-Solenopsin / Unkown
HY-N3602A rel-Cleroindicin F Inhibitor / Unkown
HY-N7534B (rel)-Epipinoresinol / Unkown
HY-RS06707 IL17REL Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS11825 Rel Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W015597S rel-3a,4,7,7a-Tetrahydro-1H-isoindole-1,3(2H)-dione-d6 99.40% Unkown
HY-W041874 cis-3-Aminocyclobutanecarboxylic acid / Unkown
HY-W1049931 rel-5,5'-((2R,5S)-2,5-Dimethylpiperazine-1,4-diyl)diisophthalic acid / Unkown
HY-W283599 Rel-(1R,2R)-cyclohex-4-ene-1,2-dicarboxylic acid / Unkown
HY-W341900 meso-α,β-Di(4-pyridyl) Glycol / Unkown
HY-W415923 rel-6-Deoxy-6-fluoroglucopyranose / Unkown
HY-W456312 (1R,2R)-rel-N1,N2-Dimethyl-N1,N2-bis(pyridin-2-ylmethyl)cyclohexane-1,2-diamine / Unkown
HY-W588220 rel-cis-Pinic acid / Unkown
HY-W753222 (aS,bS)-rel-Bedaquiline-d6 / Unkown
HY-W756041 rel-(1S,2S)-Dihydro bupropion-d9 hydrochloride / Unkown
HY-10285S1 (rel)-Saxagliptin-13C,d2 TFA Inhibitor / Unkown
HY-113995A rel-(-)-Vesamicol Inhibitor / Unkown
HY-114163A rel-ML123 / Unkown
HY-12772A rel-Hydroxy Itraconazole / Unkown
HY-129127 rel-OG-​L002 hydrochloride Inhibitor / Unkown
HY-134180 rel-Carbovir monophosphate / Unkown
HY-137372A rel-trans-Ketoconazole / Unkown
HY-14588A (rel)-Lopinavir / Unkown
HY-14645B DHMEQ racemate Inhibitor / Unkown
HY-14690B rel-Ecopipam hydrobromide Antagonist / Unkown
HY-157571S N-6-[rel-(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-pyridinamine-Sonidegib-d8 / Unkown
HY-157856 rel-4(5)-Epdpe methyl ester / Unkown
HY-157856A (Rac)-rel-4(5)-Epdpe methyl ester / Unkown
HY-165804 rel-Methyl (8Z,11Z)-13-((2S,3R)-3-pentyloxiran-2-yl)trideca-8,11-dienoate / Unkown
HY-165976 rel-(9R,10R)-9,10-Dihydroxyhexadecanoic acid / Unkown
HY-166057 trans-15,16-Epoxy-octadecanoic acid / Unkown
HY-166062 trans-5,6-Epoxy-9(Z),12(Z)-octadecadienoic acid / Unkown
HY-181455 rel-FTY720 phenoxy-biotin hydrochloride / Unkown
HY-183687 (rel)-Bedaquinoline impurity 12 Inhibitor / Unkown
HY-19153 Nepaprazole Inhibitor / Unkown
HY-90001S3 rel-Ritonavir-d6 98.66% Unkown
HY-B0492S rel-Paroxetine-d4-1 hydrochloride / Unkown
HY-B0511S1 rel-Biotin-d4 98.04% Unkown
HY-W020624 rel-Emtricitabine Inhibitor / Unkown
HY-W036661 rel-(3S,4S)-1-(tert-Butoxycarbonyl)-3-fluoropiperidine-4-carboxylic acid / Unkown
HY-W343009 rel-Biotin methyl ester / Unkown
HY-W585938 rel-(3R,4S,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride / Unkown
HY-W745349 rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride Inhibitor / Unkown
HY-W777138 rel-(1S,2R)-Dihydro bupropion-d9 Inhibitor / Unkown
HY-Z19657 rel-(R,R)-Glycopyrrolate / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Rel NCBI NCBI:5966